Kiniksa Pharmaceuticals International, plc Logo

Kiniksa Pharmaceuticals International, plc

Develops and commercializes immune-modulating therapies for debilitating diseases with unmet needs.

KNSA | NDAQ

Overview

Corporate Details

ISIN(s):
BMG5269C1010
LEI:
Country:
United States of America
Address:
23 OLD BOND STREET, FLOOR 3, LONDON
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Kiniksa Pharmaceuticals is a commercial-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for debilitating diseases with significant unmet medical needs. The company's portfolio is centered on innovative, immune-modulating assets. Its pipeline includes investigational therapies for conditions such as recurrent pericarditis, addressing diverse patient needs through novel treatments. Kiniksa operates with a patient-centric mission, aiming to deliver therapies to individuals with limited or no available treatment options.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Kiniksa Pharmaceuticals International, plc filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Kiniksa Pharmaceuticals International, plc

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Kiniksa Pharmaceuticals International, plc via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Cellectis S.A. Logo
Developing allogeneic CAR T-cell cancer immunotherapies using TALEN® gene-editing technology.
United States of America CLLS
Cellid Co., Ltd. Logo
Biotech firm developing proprietary vaccine platforms for cancer and infectious diseases.
South Korea 299660
Cellromax Science Co., Ltd. Logo
Develops health foods, derma-cosmetics, and OTC drugs for pharmacies and online channels.
South Korea 471820
CellSeed Inc. Logo
Develops cell sheet products, culture equipment, and offers contract manufacturing services.
Japan 7776
CellSource Co.,Ltd. Logo
Processes patient-derived stem cells and PRP for regenerative therapies at medical facilities.
Japan 4880
Celltrion, Inc. Logo
A biopharma pioneer developing biosimilars and novel drugs for immunology and oncology.
South Korea 068270
Celon Pharma S.A. Logo
Researches, develops, and markets innovative drugs for oncology and neurology.
Poland CLN
CEL SCI CORP Logo
Develops immunotherapies for cancer, autoimmune, and infectious diseases.
United States of America CVM
Celularity Inc Logo
Develops off-the-shelf cell therapies from placentas for cancer and aging-related diseases.
United States of America CELU
Centessa Pharmaceuticals plc Logo
Develops medicines for sleep-wake disorders, hemophilia, and other unmet medical needs.
United States of America CNTA

Talk to a Data Expert

Have a question? We'll get back to you promptly.